Key result
Neurotensin stimulates DNA synthesis and ERK/Akt phosphorylation via cell-specific PKC and EGFR transactivation pathways.
Why the study?
The mechanisms by which neurotensin promotes proliferation in human colon carcinoma cell lines are not clear.
Neurotensin mediates growth stimulation in colon and pancreatic carcinoma cells through multiple, cell-dependent signaling pathways involving PKC and EGFR transactivation.
Answers are grounded in this paper and cite their sources.
Cell-line data suggest neurotensin promotes GI cancer growth via PKC/EGFR; leaves open whether selective inhibition offers clinical benefit.
BACKGROUND: Neurotensin has been found to promote colon carcinogenesis in rats and mice, and proliferation of human colon carcinoma cell lines, but the mechanisms involved are not clear. We have examined signalling pathways activated by neurotensin in colorectal and pancreatic carcinoma cells. METHODS: Colon carcinoma cell lines HCT116 and HT29 and pancreatic adenocarcinoma cell line Panc-1 were cultured and stimulated with neurotensin or epidermal growth factor (EGF). DNA synthesis was determined by incorporation of radiolabelled thymidine into DNA. Levels and phosphorylation of proteins in signalling pathways were assessed by Western blotting. RESULTS: Neurotensin stimulated the phosphorylation of both extracellular signal-regulated kinase (ERK) and Akt in all three cell lines, but apparently did so through different pathways. In Panc-1 cells, neurotensin-induced phosphorylation of ERK, but not Akt, was dependent on protein kinase C (PKC), whereas an inhibitor of the β-isoform of phosphoinositide 3-kinase (PI3K), TGX221, abolished neurotensin-induced Akt phosphorylation in these cells, and there was no evidence of EGF receptor (EGFR) transactivation. In HT29 cells, in contrast, the EGFR tyrosine kinase inhibitor gefitinib blocked neurotensin-stimulated phosphorylation of both ERK and Akt, indicating transactivation of EGFR, independently of PKC. In HCT116 cells, neurotensin induced both a PKC-dependent phosphorylation of ERK and a metalloproteinase-mediated transactivation of EGFR that was associated with a gefitinib-sensitive phosphorylation of the downstream adaptor protein Shc. The activation of Akt was also inhibited by gefitinib, but only partly, suggesting a mechanism in addition to EGFR transactivation. Inhibition of PKC blocked neurotensin-induced DNA synthesis in HCT116 cells. CONCLUSIONS: While acting predominantly through PKC in Panc-1 cells and via EGFR transactivation in HT29 cells, neurotensin used both these pathways in HCT116 cells. In these cells, neurotensin-induced activation of ERK and stimulation of DNA synthesis was PKC-dependent, whereas activation of the PI3K/Akt pathway was mediated by stimulation of metalloproteinases and subsequent transactivation of the EGFR. Thus, the data show that the signalling mechanisms mediating the effects of neurotensin involve multiple pathways and are cell-dependent.
No takes yet. Share an insight, caveat, or question.
Müller et al. (2011) studied Colorectal and pancreatic carcinoma (cell lines). Neurotensin vs. Control / EGF was evaluated on DNA synthesis and protein phosphorylation (ERK, Akt) (p=<0.05). Neurotensin stimulated DNA synthesis and ERK/Akt phosphorylation via multiple, cell-dependent pathways, acting predominantly through PKC in Panc-1 cells, via EGFR transactivation in HT29 cells, and using both pathways in HCT116 cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: